Impact on Tremor in Phase Three Trials of Tavapadon: A Selective D1/D5 Agonist for Treatment of Parkinson’s Disease (P8-17.005)

Diego Torres-Russotto; Linda Harmer; Tracy Nicholson; Perminder Bhatia

doi:10.1212/wnl.0000000000216870

June 9, 2026Neurology

Impact on Tremor in Phase Three Trials of Tavapadon: A Selective D1/D5 Agonist for Treatment of Parkinson’s Disease (P8-17.005)

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the effect of tavapadon, a selective D1/D5 agonist, on tremor severity in Parkinson's disease.
Phase three trials evaluating tremor impact using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).
Tavapadon significantly reduced tremors as measured by MDS-UPDRS items, though specific metrics are not detailed.

Implication

Evaluates tremor reduction in Parkinson’s disease, highlighting potential therapeutic benefits of tavapadon.

Abstract

Evaluate the effect of tavapadon on tremor, as assessed by items on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Torres-Russotto et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f0566b2 https://doi.org/10.1212/wnl.0000000000216870

View at Publisher

Ask AI

Bookmark

Share

Impact on Tremor in Phase Three Trials of Tavapadon: A Selective D1/D5 Agonist for Treatment of Parkinson’s Disease (P8-17.005)

Key Points

Implication

Abstract

Discussion

Cite This Study

Impact on Tremor in Phase Three Trials of Tavapadon: A Selective D1/D5 Agonist for Treatment of Parkinson’s Disease (P8-17.005)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology